Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
RESEARCH TOOLSreports
Total Valuation
Biodexa Pharmaceuticals has a market cap or net worth of $768.88K. The enterprise value is ―.
Market Cap$768.88K
Enterprise Value―
Share Statistics
Biodexa Pharmaceuticals has 5,050,631 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,050,631
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biodexa Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -147.40%.
Return on Equity (ROE)-1.51
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-147.40%
Return on Capital Employed (ROCE)-1.61
Revenue Per Employee29.31K
Profits Per Employee-544.54K
Employee Count13
Asset Turnover0.04
Inventory Turnover-5.78
Valuation Ratios
The current PE Ratio of Biodexa Pharmaceuticals is >-0.01. Biodexa Pharmaceuticals’s PEG ratio is >-0.01.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, Biodexa Pharmaceuticals had revenue of 381.00K and earned -7.08M in profits. Earnings per share was -224.13.
Revenue381.00K
Gross Profit-3.69M
Operating Income-8.01M
Pretax Income-7.49M
Net Income-7.08M
EBITDA-7.16M
Earnings Per Share (EPS)-224.13
Cash Flow
In the last 12 months, operating cash flow was -7.75M and capital expenditures -22.00K, giving a free cash flow of -7.77M billion.
Operating Cash Flow-7.75M
Free Cash Flow-7.77M
Free Cash Flow per Share-1.54
Dividends & Yields
Biodexa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-95.31%
50-Day Moving Average1.36
200-Day Moving Average4.62
Relative Strength Index (RSI)39.67
Average Volume (3m)2.42M
Important Dates
Biodexa Pharmaceuticals upcoming earnings date is Sep 11, 2025, TBA Not Confirmed.
Last Earnings DateApr 11, 2025
Next Earnings DateSep 11, 2025
Ex-Dividend Date―
Financial Position
Biodexa Pharmaceuticals as a current ratio of 1.26, with Debt / Equity ratio of 8.74%
Current Ratio1.26
Quick Ratio1.39
Debt to Market Cap0.00
Net Debt to EBITDA0.77
Interest Coverage Ratio-195.46
Taxes
In the past 12 months, Biodexa Pharmaceuticals has paid -406.00K in taxes.
Income Tax-406.00K
Effective Tax Rate0.05
Enterprise Valuation
Biodexa Pharmaceuticals EV to EBITDA ratio is 0.54, with an EV/FCF ratio of 0.54.
EV to Sales-10.09
EV to EBITDA0.54
EV to Free Cash Flow0.54
EV to Operating Cash Flow0.56
Balance Sheet
Biodexa Pharmaceuticals has $5.05M in cash and marketable securities with £382.00K in debt, giving a net cash position of -$4.67M billion.
Cash & Marketable Securities$5.05M
Total Debt£382.00K
Net Cash-$4.67M
Net Cash Per Share-$0.93
Tangible Book Value Per Share$54.99
Margins
Gross margin is -5249.40%, with operating margin of -2103.41%, and net profit margin of -1858.01%.
Gross Margin-5249.40%
Operating Margin-2103.41%
Pretax Margin-1964.57%
Net Profit Margin-1858.01%
EBITDA Margin-1879.53%
EBIT Margin-1953.81%
Analyst Forecast
The average price target for Biodexa Pharmaceuticals is $18.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.00
Price Target Upside1465.22% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast-83.72%
EPS Growth Forecast99.56%